Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Petros Grivas, MD, PhD, University of Washington, Seattle, WA, discusses KRAS G12C as an emerging target for urothelial carcinoma and the ongoing research into this rare, although important mutation. This interview was recorded at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.